338 related articles for article (PubMed ID: 7538237)
1. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
[TBL] [Abstract][Full Text] [Related]
2. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
[TBL] [Abstract][Full Text] [Related]
5. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
7. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
McLeod DG; Schellhammer PF; Vogelzang NJ; Soloway MS; Sharifi R; Block NL; Venner PM; Patterson AL; Sarosdy MF; Kelley RP; Kolvenbag GJ
Prostate; 1999 Sep; 40(4):218-24. PubMed ID: 10420149
[TBL] [Abstract][Full Text] [Related]
8. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.
Akaza H; Yamaguchi A; Matsuda T; Igawa M; Kumon H; Soeda A; Arai Y; Usami M; Naito S; Kanetake H; Ohashi Y
Jpn J Clin Oncol; 2004 Jan; 34(1):20-8. PubMed ID: 15020659
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
Kolvenbag GJ; Blackledge GR; Gotting-Smith K
Prostate; 1998 Jan; 34(1):61-72. PubMed ID: 9428389
[TBL] [Abstract][Full Text] [Related]
10. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
Usami M; Akaza H; Arai Y; Hirano Y; Kagawa S; Kanetake H; Naito S; Sumiyoshi Y; Takimoto Y; Terai A; Yoshida H; Ohashi Y
Prostate Cancer Prostatic Dis; 2007; 10(2):194-201. PubMed ID: 17199134
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Crawford ED
Urology; 1995 Dec; 46(6):899-901. PubMed ID: 7502440
[No Abstract] [Full Text] [Related]
12. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Leibowitz RL; Tucker SJ
Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
[TBL] [Abstract][Full Text] [Related]
13. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Boccardo F; Rubagotti A; Barichello M; Battaglia M; Carmignani G; Comeri G; Conti G; Cruciani G; Dammino S; Delliponti U; Ditonno P; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Spano G
J Clin Oncol; 1999 Jul; 17(7):2027-38. PubMed ID: 10561254
[TBL] [Abstract][Full Text] [Related]
14. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Sarosdy MF; Schellhammer PF; Johnson R; Carroll K; Kolvenbag GJ
Urology; 2000 Mar; 55(3):391-5; discussion 395-6. PubMed ID: 10699617
[TBL] [Abstract][Full Text] [Related]
15. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
[TBL] [Abstract][Full Text] [Related]
16. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Roach M; Moughan J; Lawton CAF; Dicker AP; Zeitzer KL; Gore EM; Kwok Y; Seider MJ; Hsu IC; Hartford AC; Horwitz EM; Yamoah K; Jones CU; Michalski JM; Lee WR; Pisansky TM; Rabinovitch R; Rotman M; Pryzant RM; Kim HE; Thomas CR; Shipley WU; Sandler HM
Lancet Oncol; 2018 Nov; 19(11):1504-1515. PubMed ID: 30316827
[TBL] [Abstract][Full Text] [Related]
17. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
[TBL] [Abstract][Full Text] [Related]
18. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
[TBL] [Abstract][Full Text] [Related]
19. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
Boccardo F; Barichello M; Battaglia M; Carmignani G; Comeri G; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Cortellini P; Rigatti P; Usai E; Rubagotti A;
Eur Urol; 2002 Nov; 42(5):481-90. PubMed ID: 12429158
[TBL] [Abstract][Full Text] [Related]
20. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
